Innovent Biologics saw the highest growth of 2.49% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.16% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Innovent Biologics‘s patent filings and grants. Buy the databook here.
Innovent Biologics has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), World Intellectual Property Organization(WIPO), Japan(JP), and United States(US) patent Office are among the top ten patent offices where Innovent Biologics is filings its patents. Among the top granted patent authorities, Innovent Biologics has 100% of its grants in Spain(ES).
Roche could be the strongest competitor for Innovent Biologics
Patents related to climate change lead Innovent Biologics's portfolio
Innovent Biologics has the highest number of patents in climate change. For climate change, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Non-alcoholic steatohepatitis (nash) related patents lead Innovent Biologics portfolio followed by diabetes, and obesity
Innovent Biologics has highest number of patents in non-alcoholic steatohepatitis (nash) followed by diabetes, obesity.
For comprehensive analysis of Innovent Biologics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.